Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

PMV Pharmaceuticals Q3 2026 Results: Net Loss of $34.4M, Loss Widens

PMV Pharmaceuticals reported a significant increase in total liabilities to $54.3 million as of September 30, 2026, primarily driven by a new $43.6 million warrant liability. The company's cash and marketable securities totaled approximately $108.5 million, while the accumulated deficit grew to $517.0 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-34.4-21.1
Net income-34.4-21.1
EPS (diluted, $ a share)$-0.52$-0.40

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: PMVP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

PMV Pharmaceuticals, Inc.: key numbers

Share price
$1.19Close, Nov 16
Market cap
$89.9M
Shares outstanding
75.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from PMV Pharmaceuticals, Inc.

All →
8:00 AM ET 8-K
Financial Results

PMV Pharmaceuticals Financial Results

PMV Pharmaceuticals reported a net loss of $34.4 million for the third quarter of 2026, primarily driven by a non-cash loss related to warrant liabilities. The company ended the period with $108.5 million in cash, bolstered by a $50 million public offering in August, which is expected to fund operations into early 2028. Key clinical progress includes the completion of enrollment for the rezatapopt Phase 2 ovarian cancer cohort with an NDA submission planned for Q1 2027.

Term
Q3 2026

“The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need. The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation.”

David Mack, Ph.D., President and Chief Executive Officer
9:00 AM ET 8-K
Executive Compensation

PMV Pharmaceuticals Executive Compensation

PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors, effective October 1, 2026. Dr. Eckler will receive an annual cash retainer of $40,000 and was granted an initial stock option award for 84,000 shares under the company's Outside Director Compensation Policy. The appointment comes as the company prepares for a planned NDA submission for rezatapopt in early 2027.

Counterparty
Dr. Matthew Eckler
Term
through 2029 Annual Meeting

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.